Halozyme Therapeutics, Inc. (HALO) Income Statement
HALO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsHALO revenue and net income
Where HALO's revenue goes
2025Each bar shows an amount and its share of revenue. HALO kept 22.7% of revenue as net income.
HALO profit margins
HALO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +37.6% | +28.4% | +39.2% | +26.3% |
| Gross profit | +36.4% | +30.9% | +39.1% | +27.1% |
| Operating income | +45.5% | +44.2% | +41.0% | — |
| Net income | −28.6% | +16.2% | +19.7% | — |
| EPS (diluted) | −2.4% | +23.0% | +35.6% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
HALO quarterly EPS vs estimates
Halozyme Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 2, 2026 (estimate $2.16).
HALO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M | $267.6M | $196.0M | $151.9M | $316.6M | $146.7M |
| Cost of revenue | $228.8M | $159.4M | $192.4M | $139.3M | $81.4M | $43.4M | $45.5M | $10.1M | $31.2M | $33.2M |
| Gross profit | $1.17B | $855.9M | $636.9M | $520.8M | $361.9M | $224.2M | $150.4M | $141.7M | $285.5M | $113.5M |
| Research & development | $81.5M | $79.0M | $76.4M | $66.6M | $35.7M | $34.2M | $140.8M | $150.3M | $150.6M | $150.8M |
| Sales, general & admin | $207.1M | $154.3M | $149.2M | $143.5M | $50.3M | $45.7M | $77.3M | $60.8M | $53.8M | $45.9M |
| Total operating expenses | $365.2M | $304.4M | $299.3M | $253.3M | $86.0M | $80.0M | $218.1M | $211.1M | $204.5M | $196.7M |
| Operating income | $802.6M | $551.5M | $337.6M | $267.5M | $275.9M | $144.3M | −$67.6M | −$69.3M | $81.0M | −$83.2M |
| Interest income | — | — | — | — | — | — | $4.6M | $10.5M | $19.4M | $18.7M |
| Interest expense | $18.1M | $18.1M | $18.8M | $16.9M | $7.5M | $20.4M | $11.6M | $18.0M | $22.0M | $20.0M |
| Income before taxes | $466.9M | $557.1M | $348.3M | $248.9M | $248.5M | $129.3M | −$72.3M | −$79.8M | $61.6M | −$101.9M |
| Income taxes | $150.0M | $113.0M | $66.7M | $46.8M | −$154.2M | $217,000 | −$11,000 | $537,000 | −$1.4M | $1.2M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M | −$72.2M | −$80.3M | $63.0M | −$103.0M |
| EBITDA | $573.1M | $656.5M | $451.9M | $315.5M | $278.9M | $147.5M | −$63.5M | −$66.9M | $83.2M | −$80.8M |
| EPS (diluted) | $4.13 | $4.23 | $2.78 | $2.22 | $2.00 | $0.90 | −$0.50 | −$0.55 | $0.38 | −$0.81 |
| Gross margin | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% |
| Operating margin | 57.5% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | −34.5% | −45.7% | 25.6% | −56.7% |
| Net margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | −36.9% | −52.9% | 19.9% | −70.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $481.0M | $376.7M | $451.8M | $354.3M | $325.7M | $264.9M | $298.0M | $290.1M | $231.4M | $195.9M | $230.0M | $216.0M |
| Cost of revenue | $79.2M | $79.2M | $78.8M | $55.2M | $46.4M | $48.4M | $42.1M | $49.4M | $39.6M | $28.3M | $52.3M | $54.8M |
| Gross profit | $401.8M | $297.5M | $373.0M | $299.0M | $279.4M | $216.5M | $256.0M | $240.7M | $191.7M | $167.6M | $177.7M | $161.2M |
| Research & development | $27.7M | $25.6M | $31.9M | $17.3M | $17.5M | $14.8M | $20.4M | $18.5M | $21.0M | $19.1M | $21.3M | $17.3M |
| Sales, general & admin | $57.0M | $57.9M | $77.0M | $46.1M | $41.6M | $42.4M | $42.2M | $41.2M | $35.7M | $35.1M | $37.6M | $35.3M |
| Total operating expenses | $114.2M | $113.0M | $132.3M | $81.1M | $76.9M | $74.9M | $80.5M | $77.5M | $74.5M | $72.0M | $76.7M | $72.9M |
| Operating income | $287.7M | $184.5M | $240.7M | $217.9M | $202.4M | $141.5M | $175.5M | $163.2M | $117.2M | $95.5M | $101.0M | $88.3M |
| Interest expense | $5.6M | $5.5M | $4.9M | $4.3M | $4.4M | $4.5M | $4.5M | $4.5M | $4.5M | $4.5M | $5.2M | $4.5M |
| Income before taxes | $284.9M | $180.3M | −$100.8M | $219.0M | $204.9M | $143.8M | $178.2M | $165.1M | $117.7M | $96.0M | $101.2M | $101.8M |
| Income taxes | $55.0M | $30.3M | $40.7M | $43.7M | $39.8M | $25.7M | $41.2M | $28.1M | $24.5M | $19.2M | $15.8M | $19.9M |
| Net income | $229.9M | $150.0M | −$141.6M | $175.2M | $165.2M | $118.1M | $137.0M | $137.0M | $93.2M | $76.8M | $85.4M | $81.8M |
| EBITDA | $324.5M | $219.6M | −$69.3M | $243.7M | $229.8M | $168.8M | $203.2M | $190.0M | $142.6M | $120.7M | $127.1M | $129.3M |
| EPS (diluted) | $2.17 | $1.22 | −$0.24 | $1.72 | $1.54 | $1.11 | $1.26 | $1.27 | $0.91 | $0.79 | $0.82 | $0.75 |
| Gross margin | 83.5% | 79.0% | 82.6% | 84.4% | 85.8% | 81.7% | 85.9% | 83.0% | 82.9% | 85.5% | 77.3% | 74.6% |
| Operating margin | 59.8% | 49.0% | 53.3% | 61.5% | 62.2% | 53.4% | 58.9% | 56.3% | 50.7% | 48.8% | 43.9% | 40.9% |
| Net margin | 47.8% | 39.8% | −31.3% | 49.5% | 50.7% | 44.6% | 46.0% | 47.2% | 40.3% | 39.2% | 37.1% | 37.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in HALO's financial statements (latest annual report filed February 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
HALO financial results
In fiscal year 2025 (ended December 31, 2025), Halozyme Therapeutics reported revenue of $1.4 billion, up 37.6% from the year before. It had net income of $316.9 million (down 28.6%), a net profit margin of 22.7%. Diluted earnings per share came to $4.13. Over five years revenue grew at an average rate of 39.2% a year.
See the HALO stock overview for the latest quote and news, or the HALO chart for price history and technical indicators.
HALO income statement FAQ
What is Halozyme Therapeutics's annual revenue?
Halozyme Therapeutics reported total revenue of $1.4 billion for fiscal year 2025, which ended on December 31, 2025. That was up 37.6% from $1.0 billion the previous year.
Is Halozyme Therapeutics profitable?
Yes. Halozyme Therapeutics reported net income of $316.9 million in fiscal 2025, a net profit margin of 22.7%; its operating margin was 57.5%.
What is Halozyme Therapeutics's gross margin?
Halozyme Therapeutics's gross margin was 83.6% in fiscal 2025: for every $100 of revenue, Halozyme Therapeutics kept $84 after the direct cost of its products and services.
How much does Halozyme Therapeutics spend on research and development?
Halozyme Therapeutics spent $81.5 million on research and development in fiscal 2025, 5.8% of revenue.
How fast is Halozyme Therapeutics growing?
Revenue grew 39.2% a year on average over the last five fiscal years, from $267.6 million to $1.4 billion.
What are Halozyme Therapeutics's earnings per share?
Halozyme Therapeutics earned $4.13 per diluted share in fiscal 2025, compared with $4.23 a year earlier.
When will Halozyme Therapeutics report its next earnings?
Halozyme Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes.
When does Halozyme Therapeutics's fiscal year end?
Halozyme Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 17, 2026.